The Latest Breaking News from AbbVie

Adding Epcoritamab to R-CHOP Cut Lymphoma Progression or Death Risk by 51% in Topline Phase 3 Trial Results

Topline phase 3 data show epcoritamab plus R-CHOP cut progression or death risk by 51% in newly diagnosed DLBCL. Results are not yet peer-reviewed.

Medical Daily · 19h ago

Topline Phase 3 Data Show Adding Epcoritamab to Standard R-CHOP Cut Lymphoma Progression or Death Risk by 51%

Epcoritamab plus R-CHOP cut the risk of progression or death by 51% in a Phase 3 DLBCL trial, per AbbVie and Genmab. Survival and full data are pending.

Medical Daily · Oct 6

HRSA Names 10 Drugmakers and 21 Drugs for 340B Rebate Pilot as Hospitals Weigh Options Before January Launch

HRSA approved 10 drugmakers and 21 drugs, including Eliquis and Jardiance, for its 340B rebate pilot starting Jan. 1 as hospitals weigh legal options.

Medical Daily · Oct 5

How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks

AbbVie has underperformed the healthcare peers over the past year, and analysts remain very optimistic about the stock’s outlook.

Barchart · Aug 30

Advocacy Group Says a Medicare Rule Change Delayed Price Negotiation for a Costly AbbVie Drug by Seven Years

Public Citizen says a CMS eligibility change kept AbbVie's Creon out of Medicare price negotiation for seven extra years. Here is how it works.

Medical Daily · Aug 10

What Are Wall Street Analysts' Target Price for AbbVie Stock?

Despite AbbVie’s outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Barchart · Aug 3

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie posted strong Q2 revenue and EPS growth, and despite a post-earnings dip tied to the Apogee Therapeutics deal, analysts and dividend strength support shares reaching $300.

MarketBeat · Aug 2

AbbVie Earnings Preview: What to Expect

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Barchart · Jul 8

Markets Have Been Anything But Calm. Jefferies Thinks These Low-Stress Stocks Can Still Deliver Returns.

Jefferies says a group of established companies with healthy cash flow and limited momentum could offer investors a steadier place to ride out a volatile market.

International Business Times · Jul 8

AbbVie vs Eli Lilly: 1 Is Clearly the Better Dividend Stock to Buy and Hold for the Next 10 Years

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

Barchart · Jul 7